Hugo Peris, Spiral Therapeutics CEO

Hear­ing-fo­cused biotech grabs trio of pro­grams from Oton­o­my's fire sale

Oton­o­my may be shut­ting down, but the lessons learned there will live on at an­oth­er biotech work­ing on new treat­ments for hear­ing loss.

San Fran­cis­co-based Spi­ral Ther­a­peu­tics has bought cer­tain as­sets re­lat­ed to three of Oton­o­my’s pro­grams, rang­ing from da­ta, patent rights, and know-how to in­ven­to­ry. That in­cludes da­ta around Oton­o­my’s twice-failed lead pro­gram, OTO-104 (Otividex), a sus­tained-ex­po­sure for­mu­la­tion of dex­am­etha­sone.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters